HOME >> MEDICINE >> NEWS
Iressa news backgrounder: Testing of smart drug expands at M. D. Anderson Cancer Center

It is a drug suffused in promise, a next-generation therapy that has shown glimmers of powerful potential. Iressa is the kind of treatment that oncologists dream of - a pill that can be swallowed once a day, a non-toxic therapy that causes few side effects. For 10 percent of patients who have tried it, people who have no other options left for them, Iressa seems to make the difference between life and death. Another 30 percent to 40 percent of patients who have used the drug have a better, if not a longer, life.

But for most patients, Iressa does not shrink their cancer. That fact has become a challenge to researchers at The University of Texas M. D. Anderson Cancer Center. They are dedicated to solving the central puzzle that Iressa, and similar other targeted therapies, pose - what are the cancers that may best respond, and which patients will benefit?

M. D. Anderson researchers have been at the forefront of testing Iressa, as well as a slew of other experimental drugs that target critical cancer cell pathways. They have been involved in all phases of clinical trials looking at the effectiveness of Iressa in common lung cancer, work that helped lead to federal Food and Drug Administration approval of the drug in early 2003 for use when standard therapy has not helped lung cancer patients.

Now, investigators at M. D. Anderson are testing Iressa in malignant brain cancer and are poised to study it in a number of cancers, including head and neck, breast, and prostate, along with further investigations in lung cancer.

"M. D. Anderson is one of the leading institutions in developing targeted therapies such as Iressa," says Frank Fossella, M.D., professor in the Department of Thoracic/Head and Neck Medical Oncology, who has treated many lung and other head and neck cancers where it has shown tantalizing benefit.

"So far, Iressa has been a good news, bad news story. The response rates are not as high as we woul
'"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
28-Apr-2004


Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Gene mutations predict which lung cancers will respond to Iressa
2. Iressa news backgrounder
3. Chemoprevention backgrounder: Working for a future of cancer chemoprevention
4. Cancer gene therapy news backgrounder: New ideas fuel next generation gene therapy research
5. Cancer markers news backgrounder: Future of cancer diagnosis, treatment lies in tumor barcode
6. St. Jude scientist to lead NCI Pediatric Preclinical Testing Program
7. Testing drugs ability to reverse stroke after standard three-hour window has closed
8. Testing may one day pinpoint which early-stage cancer patients are at risk for relapse
9. Testing earlier for gestational diabetes a smarter way to screen pregnant women
10. Testing for alcohol problems in the workplace
11. UNC Researchers Testing First In New Class Of AIDS Drugs

Post Your Comments:
(Date:8/21/2014)... College of Chest Physicians (CHEST) announces the immediate ... Injured During Pandemics and Disasters: CHEST Consensus Statement ... journal CHEST while the global health-care ... The consensus statement aims to guide ethical decision-making, ... crises. The statement was developed by over 100 ...
(Date:8/21/2014)... (Aug. 21, 2014) An international scientific collaboration led ... genetic alterations that may contribute to a rare form ... this rare cancer but other types as well. , ... Health,s Cancer Genome Atlas initiative , completed the ... results today in the journal Cancer Cell . ...
(Date:8/21/2014)... Utah scientists have developed a genetically engineered line of ... new research on epilepsy, Alzheimer,s and other diseases. ... in degree of fluorescence in response to different calcium ... called astrocytes and microglia, to be studied in a ... to decipher how the brain works," said Petr ...
(Date:8/21/2014)... The Mount Sinai Hospital has expanded its ... captures real-time patient feedback and enables staff to make ... now available to admitted patients in the Hospital’s cardiology, ... satisfaction using smartphones. , "We are expanding our ... the timely information we need to respond to patient ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Greater awareness ... to have babies before they are full term has ... some areas of the country, early elective deliveries (EEDs) ... last 20 years, EED is defined as delivery before ... linked to neonatal morbidity and mortality, and offers no ...
Breaking Medicine News(10 mins):Health News:CHEST releases new expert guidance in care of the critically ill and injured 2Health News:Sequence of rare kidney cancer reveals unique alterations involving telomerase 2Health News:Sequence of rare kidney cancer reveals unique alterations involving telomerase 3Health News:Mouse model for epilepsy, Alzheimer's gives window into the working brain 2Health News:The Mount Sinai Hospital Expands Use of Mobile Patient Satisfaction Tool 2Health News:The Mount Sinai Hospital Expands Use of Mobile Patient Satisfaction Tool 3Health News:New “Playbook” Aims to Eliminate Early Elective Deliveries in the United States 2Health News:New “Playbook” Aims to Eliminate Early Elective Deliveries in the United States 3
(Date:8/21/2014)... , Aug. 21, 2014 InfinityQS ... and Manufacturing Intelligence , today announces Infusion ... The event will be held Oct. 9-10, 2014, ... is designed to showcase the necessity for implementing ... metrics and Manufacturing Intelligence to gain insight into ...
(Date:8/21/2014)... -- Professional Compounding Centers of America (PCCA) will ... three best scientific presentations at the sixth ... Formulating Better Medicines for Children  conference, held ... Greece , includes dozens of poster-style scientific ... three winners will be selected by a panel ...
(Date:8/21/2014)... MENLO PARK, Calif. , Aug. 21, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, announced ... ("Nat") Ricciardi to the Company,s newly expanded Board of ... now comprises eight directors, three of whom are independent. ... years of experience working with emerging growth companies. He ...
Breaking Medicine Technology:InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4
Cached News: